In today’s session Amgen, Inc. (AMGN) registered an unusually high (527) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the June, 2017 call, expecting serious AMGN increase. With 527 contracts traded and 1834 open interest for the Jun, 17 contract, it seems this is a quite bullish bet. The option with symbol: AMGN170616C00180000 closed last at: $4.15 or 18.6% up. About 3.33M shares traded hands or 4.72% up from the average. Amgen, Inc. (NASDAQ:AMGN) has declined 2.88% since March 29, 2016 and is downtrending. It has underperformed by 6.36% the S&P500.
Amgen, Inc. (NASDAQ:AMGN) Ratings Coverage
Out of 16 analysts covering Amgen Inc. (NASDAQ:AMGN), 9 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 56% are positive. $218 is the highest target while $160 is the lowest. The $188.95 average target is 32.23% above today’s ($142.9) stock price. Amgen Inc. has been the topic of 28 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The stock has “Market Perform” rating given by Bernstein on Wednesday, June 29. The rating was initiated by Credit Suisse on Wednesday, January 20 with “Outperform”. As per Tuesday, December 15, the company rating was upgraded by Morgan Stanley. The rating was initiated by Atlantic Securities with “Overweight” on Friday, December 18. Leerink Swann initiated the stock with “Market Perform” rating in Friday, February 5 report. The firm earned “Buy” rating on Monday, September 7 by UBS. The company was upgraded on Friday, August 21 by Vetr. The stock of Amgen, Inc. (NASDAQ:AMGN) earned “Market Perform” rating by Raymond James on Tuesday, September 1. On Thursday, February 25 the stock rating was initiated by Citigroup with “Neutral”. Wells Fargo initiated the stock with “Market Perform” rating in Friday, December 4 report.
According to Zacks Investment Research, “Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives.”
Insitutional Activity: The institutional sentiment increased to 1.28 in 2016 Q2. Its up 0.21, from 1.07 in 2016Q1. The ratio increased, as 56 funds sold all Amgen, Inc. shares owned while 422 reduced positions. 77 funds bought stakes while 533 increased positions. They now own 577.82 million shares or 7.76% less from 626.39 million shares in 2016Q1.
Kcm Investment Advsr Ltd has invested 0.17% of its portfolio in Amgen, Inc. (NASDAQ:AMGN). Evanson Asset Mgmt has invested 0.06% of its portfolio in Amgen, Inc. (NASDAQ:AMGN). Retirement Of Alabama has invested 0.4% of its portfolio in Amgen, Inc. (NASDAQ:AMGN). First Interstate State Bank reported 5,808 shares or 0.18% of all its holdings. Livingston Grp Asset Mngmt (Operating As Southport Cap Management) holds 0.04% or 525 shares in its portfolio. Tradewinds Cap Mngmt Lc owns 7,261 shares or 0.79% of their US portfolio. 10 has 0.64% invested in the company for 14,683 shares. Kimelman & Baird Ltd Liability Co has 0.1% invested in the company for 3,600 shares. Stoneridge Prns Ltd accumulated 3,717 shares or 0.08% of the stock. Concorde Asset Limited Liability accumulated 0.27% or 1,784 shares. Ally Fincl holds 0.89% or 35,000 shares in its portfolio. Wealthtrust has invested 0.16% of its portfolio in Amgen, Inc. (NASDAQ:AMGN). Nuveen Asset Management Ltd Llc has 447,096 shares for 0.42% of their US portfolio. Moreover, Mrj Inc has 3.36% invested in Amgen, Inc. (NASDAQ:AMGN) for 32,400 shares. Natl Planning Corporation holds 0.11% or 8,239 shares in its portfolio.
Insider Transactions: Since May 3, 2016, the stock had 0 buys, and 1 sale for $523,758 net activity. Such Annette Louise also sold $523,758 worth of Amgen, Inc. (NASDAQ:AMGN) on Monday, August 1. Another trade for 30,000 shares valued at $4.62M was made by Balachandran Madhavan on Tuesday, May 3.
Amgen Inc. is a biotechnology company. The company has a market cap of $96.69 billion. The Firm discovers, develops, makes and delivers various human therapeutics. It has a 14.27 P/E ratio. The Company’s business segment is human therapeutics.
AMGN Company Profile
Amgen Inc., incorporated on October 31, 1986, is a biotechnology company. The Firm discovers, develops, makes and delivers various human therapeutics. The Company’s business segment is human therapeutics. The Company’s marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Firm focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.
More notable recent Amgen, Inc. (NASDAQ:AMGN) news were published by: Fool.com which released: “5 Things Amgen Inc.’s Management Wants You to Know” on October 28, 2016, also Seekingalpha.com with their article: “Amgen Is Melting Down” published on October 31, 2016, Investorplace.com published: “Why McKesson Corporation (MCK), Amgen, Inc. (AMGN) and Electronic Arts Inc …” on October 28, 2016. More interesting news about Amgen, Inc. (NASDAQ:AMGN) were released by: Marketwatch.com and their article: “Amgen beats profit expectations and raises its outlook” published on October 27, 2016 as well as Nasdaq.com‘s news article titled: “Earnings Reaction History: Amgen Inc., 60.0% Follow-Through Indicator, 2.7 …” with publication date: October 27, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.